Agios Drug Patent Portfolio
Agios owns 2 orange book drugs protected by 10 US patents Given below is the list of Agios's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11878049 | Mitapivat therapy and modulators of cytochrome P450 | 31 Jul, 2041 | Active |
| US11254652 | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | 21 Nov, 2038 | Active |
| US11234976 | Methods of using pyruvate kinase activators | 11 Oct, 2038 | Active |
| US11793806 | Pyruvate kinase activators for use in therapy | 12 Apr, 2033 | Active |
| US9193701 | Pyruvate kinase activators for use in therapy | 26 Oct, 2032 | Active |
| US10632114 | Pyruvate kinase activators for use in therapy | 03 May, 2032 | Active |
| US9682080 | Pyruvate kinase activators for use in therapy | 03 May, 2032 | Active |
| US9980961 | Pyruvate kinase activators for use in therapy | 03 May, 2032 | Active |
| USRE49582 | Therapeutic compounds and compositions | 24 Feb, 2031 | Active |
| US8785450 | Therapeutic compounds and compositions | 24 Feb, 2031 | Active |
Latest Legal Activities on Agios's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Agios.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Aug, 2025 | US11254652 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Aug, 2025 | US11254652 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Aug, 2025 | US11234976 |
| Mail Patent eCofC Notification | 01 Jul, 2025 | US11254652 |
| Email Notification | 01 Jul, 2025 | US11254652 |
| Patent eCofC Notification | 01 Jul, 2025 | US11254652 |
| Recordation of Patent eCertificate of Correction | 01 Jul, 2025 | US11254652 |
| Mail Patent eCofC Notification | 01 Jul, 2025 | US11254652 |
| Recordation of Patent eCertificate of Correction | 01 Jul, 2025 | US11254652 |
| Email Notification | 01 Jul, 2025 | US11254652 |
| Patent eCofC Notification | 01 Jul, 2025 | US11254652 |
| Withdrawal of Application for PTE | 25 Jun, 2025 | US9193701 |
| Withdrawal of Application for PTE | 25 Jun, 2025 | US9193701 |
| Post Issue Communication - Certificate of Correction | 13 Jun, 2025 | US11254652 |
| Post Issue Communication - Certificate of Correction | 13 Jun, 2025 | US11254652 |
Agios's Family Patents
Agios Drug List
Given below is the complete list of Agios's drugs and the patents protecting them.
1. Aqvesme
Aqvesme is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11878049 | Mitapivat therapy and modulators of cytochrome P450 |
31 Jul, 2041
(15 years from now)
| Active |
| US11254652 | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
21 Nov, 2038
(12 years from now)
| Active |
| US9193701 | Pyruvate kinase activators for use in therapy |
26 Oct, 2032
(6 years from now)
| Active |
| US10632114 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| US9682080 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| USRE49582 | Therapeutic compounds and compositions |
24 Feb, 2031
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aqvesme's drug page
2. Pyrukynd
Pyrukynd is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11878049 | Mitapivat therapy and modulators of cytochrome P450 |
31 Jul, 2041
(15 years from now)
| Active |
| US11254652 | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
21 Nov, 2038
(12 years from now)
| Active |
| US11234976 | Methods of using pyruvate kinase activators |
11 Oct, 2038
(12 years from now)
| Active |
| US11793806 | Pyruvate kinase activators for use in therapy |
12 Apr, 2033
(7 years from now)
| Active |
| US9193701 | Pyruvate kinase activators for use in therapy |
26 Oct, 2032
(6 years from now)
| Active |
| US10632114 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| US9682080 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| US9980961 | Pyruvate kinase activators for use in therapy |
03 May, 2032
(6 years from now)
| Active |
| US8785450 | Therapeutic compounds and compositions |
24 Feb, 2031
(4 years from now)
| Active |
| USRE49582 | Therapeutic compounds and compositions |
24 Feb, 2031
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pyrukynd's drug page